BERLIN, GERMANY, 29 October 2025 — Earlybird Health has announced the appointment of Dr. Rabab Nasrallah and Dr. Christoph Massner to Partners. The promotions acknowledge their leadership in shaping the firm’s investment strategy and portfolio management across biotech and data-enabled therapeutic platforms, devices, and tools. This transition recognizes their vision and mindset to back companies at the intersection of science and data.

“Rabab and Chris combine discipline and bold thinking. As they step into the partnership, they will help lead the future of Earlybird Health,” said Thom Rasche, Partner at Earlybird Health. “They have each helped shape how we evaluate opportunities, support portfolio teams, and translate innovation into clinical impact.”

Chris brings a commercial-led mindset shaped by work across data-enabled health technologies, diagnostics, platform tools, and device-enabled therapeutics. Since joining Earlybird in 2018, he has led several transactions across Earlybird Health I & II, with a focus on business models that translate from tech into healthcare. He is known for articulating how data and AI create value in patient care and product development. Chris serves on the boards of Noscendo, Ariceum Therapeutics, and Hilo, and holds board observer roles at Shape Memory Medical and Alesi Surgical. Beyond portfolio work, he actively builds bridges between tech investors, corporates, and our health portfolio.

Rabab brings a therapeutics and platform-led investment perspective with a strong record of execution, having closed several transactions across Earlybird Health I & II. Since joining Earlybird in 2020, she has executed deals end-to-end and co-developed the firm's biotech investment strategy with clear value-inflection plans and capital discipline. Rabab maintains a deep network across VC and strategic pharma in Europe and the US, using those relationships to build high-quality syndicates and partnerships to support companies with breakthrough technologies. She serves on the boards of HAYA Therapeutics, Greywolf Therapeutics, and Portal Biotech, and is a board observer at GEMMABio, Priothera, ImCheck Therapeutics, and Prothea Technologies. Beyond investing, she engages with stakeholders to understand how platform scale in biotech can be realized and valued alongside individual assets. 

Rabab and Chris bring complementary sector depth and a holistic view across healthcare. Together, they’ve shaped how Earlybird Health sources and evaluates opportunities, structures and governs investments, and partners with companies through key inflection points. Within the firm, they’ve taken on broader leadership roles in management and operations. This combination anchors Earlybird Health’s approach to backing companies that operate with rigor and quality while pursuing bold, future-oriented opportunities in healthcare.

About Earlybird & Earlybird Health

Founded in 1997, Earlybird backs exceptional early-stage companies across Europe, providing capital, strategic guidance, and access to global networks. Earlybird Health partners with founders building breakthrough health innovations across biotech, medtech, and data-driven health. With more than €2.5 billion under management, nine IPOs, and over 36 trade sales, Earlybird is one of Europe’s most established venture capital firms.

Media Contact

Dr. Freskida Goni, freskida@earlybird.com

Health Communications and Public Relations